Long Noncoding RNA LINC00152 is a Potential Prognostic Biomarker in Patients with High-grade Glioma

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2018 Mar 27

PMID 29577647

Citations 15

Authors

Wen Wang

Fan Wu

Zheng Zhao

Kuan-Yu Wang

Ruo-Yu Huang

Hao-Yuan Wang

Qing Lan

Jiang-Fei Wang

Ji-Zong Zhao

Affiliations

Soon will be listed here.

Abstract

Aims: To investigate the role of LINC00152 in high-grade glioma (HGG).

Methods: We collected data from the Chinese Glioma Genome Atlas (CGGA) microarray, CGGA RNA sequencing, and GSE16011 datasets to evaluate the expression and prognostic relationship of LINC00152 in patients with HGGs. A knockdown assay was performed to determine the function of LINC00152 in glioma development and progression in vitro and in vivo.

Results: The expression of LINC00152 was increased with glioma grade, especially in the mesenchymal TCGA subtype. LINC00152 was independently associated with poor prognosis, and the overall survival (OS) of the high expression group was shorter than the low expression group (median OS 14.77 vs 9.65 months; P = 0.0216) in the CGGA microarray dataset. The results were validated in the other 2 datasets. Based on the expression of LINC00152, 4288 (2519 positively; 1769 negatively) probes were extracted to perform a biological process analysis using the Database for Annotation, Visualization, and Integrated Discovery. Positively regulated genes were enriched in immune response, apoptotic process, cell adhesion, and regulation of cell proliferation. The clinical and molecular features of HGG patients indicated that patients in the LINC00152 high expression group tended to display the mesenchymal type, older (≥46 years), isocitrate dehydrogenase1 wild-type, O(6)-methylguanine DNA methyltransferase unmethylated, nonchemotherapy, and low karnofsky performance status. Functionally, knockdown of LINC00152 inhibited cell proliferation, migration, and invasion and increased the sensitivity of chemotherapy in vitro.

Conclusion: Our results indicate that knockdown of LINC00152 could inhibit tumor growth in vivo. LINC00152 could serve as a potential prognostic biomarker in patients with HGG.

Citing Articles

Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.

Sharma S Noncoding RNA Res. 2024; 9(4):1203-1221.

PMID: 39036603 PMC: 11259994. DOI: 10.1016/j.ncrna.2024.05.009.

Targeting LINC00152 activates cAMP/Ca/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

Saatci O, Alam R, Huynh-Dam K, Isik A, Uner M, Belder N Cell Death Dis. 2024; 15(6):418.

PMID: 38879508 PMC: 11180193. DOI: 10.1038/s41419-024-06814-3.

Targeting LINC00152 activates cAMP/Ca/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

Saatci O, Alam R, Huynh-Dam K, Isik A, Uner M, Belder N bioRxiv. 2024; .

PMID: 38496603 PMC: 10942410. DOI: 10.1101/2023.11.05.565697.

Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets.

Kciuk M, Yahya E, Mohamed M, Abdulsamad M, Allaq A, Gielecinska A Cancers (Basel). 2023; 15(13).

PMID: 37444408 PMC: 10340789. DOI: 10.3390/cancers15133298.

lncRNA cytoskeleton regulator RNA (CYTOR): Diverse functions in metabolism, inflammation and tumorigenesis, and potential applications in precision oncology.

Ou C, He X, Liu Y, Zhang X Genes Dis. 2023; 10(2):415-429.

PMID: 37223495 PMC: 10201560. DOI: 10.1016/j.gendis.2021.08.012.

References

Wang W, Wu F, Zhao Z, Wang K, Huang R, Wang H . Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma. CNS Neurosci Ther. 2018; 24(10):957-966. PMC: 6489806. DOI: 10.1111/cns.12850. View

Deguchi S, Katsushima K, Hatanaka A, Shinjo K, Ohka F, Wakabayashi T . Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene. 2017; 36(32):4629-4640. DOI: 10.1038/onc.2017.88. View

Sun Y, Wang Z, Zhou D . Long non-coding RNAs as potential biomarkers and therapeutic targets for gliomas. Med Hypotheses. 2013; 81(2):319-21. DOI: 10.1016/j.mehy.2013.04.010. View

Mercer T, Dinger M, Mattick J . Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10(3):155-9. DOI: 10.1038/nrg2521. View

Nikiforova M, Hamilton R . Molecular diagnostics of gliomas. Arch Pathol Lab Med. 2011; 135(5):558-68. DOI: 10.5858/2010-0649-RAIR.1. View

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev. 2003; (4):CD003913. PMC: 10625440. DOI: 10.1002/14651858.CD003913. View

Wang Y, Wu P, Lin R, Rong L, Xue Y, Fang Y . LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Sci Rep. 2015; 5:13749. PMC: 4557127. DOI: 10.1038/srep13749. View

Wang P, Ren Z, Sun P . Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem. 2012; 113(6):1868-74. DOI: 10.1002/jcb.24055. View

10.

Karsy M, Neil J, Guan J, Mahan M, Mark M, Colman H . A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 2015; 38(3):E4. DOI: 10.3171/2015.1.FOCUS14755. View

11.

Yan W, Zhang W, You G, Zhang J, Han L, Bao Z . Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012; 14(12):1432-40. PMC: 3499016. DOI: 10.1093/neuonc/nos263. View

12.

Wang W, Zhang L, Wang Z, Yang F, Wang H, Liang T . A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget. 2016; 7(43):69991-69999. PMC: 5342529. DOI: 10.18632/oncotarget.11726. View

13.

Zhang X, Leung G . Long non-coding RNAs in glioma: functional roles and clinical perspectives. Neurochem Int. 2014; 77:78-85. DOI: 10.1016/j.neuint.2014.05.008. View

14.

Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J . Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res. 2015; 34:135. PMC: 4632266. DOI: 10.1186/s13046-015-0250-6. View

15.

Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan G . HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget. 2016; 7(12):14429-40. PMC: 4924726. DOI: 10.18632/oncotarget.7418. View

16.

Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y . Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 2014; 4:6088. PMC: 4133709. DOI: 10.1038/srep06088. View

17.

Ji J, Tang J, Deng L, Xie Y, Jiang R, Li G . LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget. 2015; 6(40):42813-24. PMC: 4767473. DOI: 10.18632/oncotarget.5970. View

18.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

19.

Yang P, Wang Y, Peng X, You G, Zhang W, Yan W . Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013; 113(2):259-66. DOI: 10.1007/s11060-013-1103-9. View

20.

Cheng W, Li M, Cai J, Wang K, Zhang C, Bao Z . HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. J Neurooncol. 2015; 122(2):303-12. PMC: 4368847. DOI: 10.1007/s11060-014-1709-6. View